Summit Therapeutics Inc. (SMMT) stock forecast & analysis
14.15
NasdaqGM · USDDelayed by 15 minutes
Down: -0.93, -6.1%
1 analysis
Latest analysis: · verdict locked
- Open
- 15.20
- Previous close
- 15.08
- Day range
- 14.06 – 15.20
- 52-week range
- 12.07 – 29.23
- Volume (shares)
- 5.56M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 799.76M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- -1.52
- Market cap
- 11.32B
Market Scanner’s AI analysis of Summit Therapeutics Inc. (SMMT), updated November 2026: Summit Therapeutics' stock price below key moving averages, with a bearish technical trend structure.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Summit Therapeutics Inc. (SMMT) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Summit Therapeutics' stock price below key moving averages, with a bearish technical trend structure.
Recent analyses covered Summit Therapeutics' (SMMT) technical indicators, noting the stock price is below its 50-day and 200-day moving averages, indicating a downtrend. Momentum has weakened following a brief recovery. The company is pre-revenue, with its investment case relying on pipeline progress and cash reserves rather than earnings. News flow analysis was limited by data availability, with one headline identified as a potential name collision with a UK automotive trade body.
SMMT news & sentiment
News flow analysis was limited, with one headline potentially misattributed. Social media discussion and sentiment were not covered in the provided notes.
SMMT technical picture
The stock price is below its 50-day and 200-day moving averages, indicating a downtrend on both timeframes. Short-term momentum has weakened after a brief recovery, with the 50-day moving average showing signs of rolling over toward the 200-day moving average.
Fundamentals
Summit Therapeutics is a pre-revenue company whose investment case rests on cash reserves and pipeline progress. Its only reported revenue was in FY2022, and its balance sheet figures for the latest quarter show total debt of $19.98M.
Factors discussed — upside
- Wall Street analysts see potential upside to the stock.
Factors discussed — risks
- Price is below the 50-day and 200-day SMAs.
- 50-day SMA is rolling over toward the 200-day SMA.
- Short-term momentum has weakened.
- Company is pre-revenue.
- technical analysis
- fundamental analysis
- news flow
Summary updated .
SMMT technical indicators
Common technical indicators for SMMT, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 16.41 | Price below |
| 10-day exponential moving average | 15.79 | Price below |
| Relative strength index (14-day) | 42.17 | Neutral |
| MACD line (12/26/9) | -0.0874 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 13.83 – 17.69 | Price inside the bands |
Analyses
Recent SMMT.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-14 SMMT.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Summit Therapeutics Inc.?
- Recent analyses noted that Wall Street analysts perceive potential upside for the company.
- What are the risks for Summit Therapeutics Inc.?
- The company's stock price is currently below its 50-day and 200-day moving averages, with the 50-day average trending downwards towards the 200-day average. Short-term momentum has also weakened, and the company is pre-revenue.
- Is Summit Therapeutics Inc. bullish or bearish?
- Recent AI analyses of Summit Therapeutics Inc. examined factors on both sides. Discussed upside: Recent analyses noted that Wall Street analysts perceive potential upside for the company. Discussed risks: The company's stock price is currently below its 50-day and 200-day moving averages, with the 50-day average trending downwards towards the 200-day average. Short-term momentum has also weakened, and the company is pre-revenue. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Summit Therapeutics Inc.?
- News flow analysis was limited, with one headline potentially misattributed. Social media discussion and sentiment were not covered in the provided notes.
- How does Market Scanner analyse Summit Therapeutics Inc.?
- Every analysis of Summit Therapeutics Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Summit Therapeutics Inc.?
Recent analyses noted that Wall Street analysts perceive potential upside for the company.
What are the risks for Summit Therapeutics Inc.?
The company's stock price is currently below its 50-day and 200-day moving averages, with the 50-day average trending downwards towards the 200-day average. Short-term momentum has also weakened, and the company is pre-revenue.
Is Summit Therapeutics Inc. bullish or bearish?
Recent AI analyses of Summit Therapeutics Inc. examined factors on both sides. Discussed upside: Recent analyses noted that Wall Street analysts perceive potential upside for the company. Discussed risks: The company's stock price is currently below its 50-day and 200-day moving averages, with the 50-day average trending downwards towards the 200-day average. Short-term momentum has also weakened, and the company is pre-revenue. These are descriptive observations, not a recommendation.
What is the latest sentiment on Summit Therapeutics Inc.?
News flow analysis was limited, with one headline potentially misattributed. Social media discussion and sentiment were not covered in the provided notes.
How does Market Scanner analyse Summit Therapeutics Inc.?
Every analysis of Summit Therapeutics Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- claude-medium-v2
Run a fresh SMMT.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.